14 completed, 12 unknown, 11 recruiting, 5 not yet recruiting. 9 Phase 1, 9 Phase 2, 7 Not applicable, 4 Early Phase 1, 2 Phase 4.
Follow SLE: new trials by email Literature Review of SLE trials Research Report on SLE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Uromodulin as a Biomarker in Lupus Nephritis Uromodulin, SLE | Not yet recruiting | Assiut University | 90 | 2026-10-01 | 2026-08-13 | |
| Safety and Efficacy of ONT01 in Lupus ONT01 is a small molecule CD11b modulator. - Lupus Nephritis (LN), Lupus Nephritis - WHO Class III | Early Phase 1 | Recruiting | Hospital for Special Surgery, New York | 61 | 2026-09-04 | 2025-11-20 |
| Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus SLE | Not yet recruiting | Assiut University | 150 | 2026-08-30 | 2025-09-02 | |
| Prediction of SLE Flares Using Patient-Reported Outcomes and Machine Learning Patient-Reported Questionnaire (PROs) - SLE | Recruiting | Sohag University | 500 | 2026-06-30 | 2026-10-22 | |
| Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus CRC01 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Not yet recruiting | Curocell Inc. | 39 | 2026-02-01 | 2026-01-23 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus VENT-03, Placebo - Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus | Phase 2 | Recruiting | Ventus Therapeutics U.S., Inc. | 24 | 2025-12-03 | 2026-10-05 |
| A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. RD06-05 CART Cell Injection - SLE, LN | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 96 | 2025-07-24 | 2026-08-03 |
| Evaluating Mental Health Challenges in Juvenile Lupus Erythematosus and Their Caregivers The multidimensional peer victimization scale (PVS) - SLE | Not yet recruiting | Assiut University | 62 | 2025-06-01 | 2025-02-04 | |
| CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus CART19 - SLE, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 24 | 2025-05-06 | 2026-09-24 |
| Assessment of Blood Indices in Systemic Lupus Erythematosus SLE, Blood Indices | Not yet recruiting | Assiut University | 70 | 2025-05-01 | 2025-03-12 | |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus CLN-978 - SLE, SLE (Systemic Lupus) | Phase 1 | Recruiting | Cullinan Therapeutics Inc. | 24 | 2025-01-21 | 2026-10-26 |
| UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients Physical examination, Electrocardiogram, SF-36 questionnaire - SLE, Lupus | Phase 1 | Recruiting | LiveKidney.Bio | 10 | 2025-01-07 | 2025-09-11 |
| Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases RD06-05 CART Cell Injection - SLE, Systemic Sclerosis | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 18 | 2025-01-03 | 2026-02-02 |
| Phase 1b/2a in SLE With Budoputug budoprutug - Systemic Lupus Erythematosus, SLE | Phase 1 / Phase 2 | Withdrawn | Tenet Medicines | 2025-01-01 | 2024-10-16 | |
| Pregnancies Before the Diagnosis of Systemic Lupus Erythematosus Collect data on all pregnancies before and after diagnosis of SLE. - Pregnancy Complications, SLE | Recruiting | University of Algiers | 50 | 2025-01-01 | 2025-12-31 | |
| Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Shingrix, vaccination with 2 doses of Shingrix vaccine - Systemic Vasculitis, Spondylarthropathies | Phase 4 | Enrolling by invitation | Region Skane | 240 | 2024-12-17 | 2025-01-10 |
| A Study of RD06-04 in Patients With Active Autoimmune Diseases RD06-04 cell infusion - SLE, Sclerosis | Early Phase 1 | Withdrawn | Nanjing Bioheng Biotech Co., Ltd. | 2024-08-31 | 2026-02-03 | |
| A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. APG-2575, Placebo - SLE | Phase 1 / Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 40 | 2024-08-09 | 2025-12-16 |
| AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus AB-101, Cyclophosphamide, Fludarabine - Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | Phase 1 | Active not recruiting | Artiva Biotherapeutics, Inc. | 51 | 2024-04-03 | 2025-12-10 |
| Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases COVID-19 vaccine and booster training, and importance - Rheumatic Diseases, COVID-19 Vaccine | Not applicable | Active not recruiting | Northwestern University | 60 | 2024-03-15 | 2026-05-29 |
Showing 20 of 52. Sign in to see all of them.
Lupus Erythematosus, Systemic (18) · Lupus Nephritis (6) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Arthritis, Rheumatoid (3) · Atherosclerosis (2) · Autoimmune Diseases (2) · COVID-19 (2) · Rheumatic Diseases (2) · Scleroderma, Diffuse (2) · Anti-Glomerular Basement Membrane Disease (1) · Arthritis (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Cardiovascular Diseases (1) · Connective Tissue Diseases (1)
Skin and Connective Tissue Diseases (30) · Connective Tissue Diseases (27) · Immune System Diseases (27) · Autoimmune Diseases (26) · Female Urogenital Diseases and Pregnancy Complications (8) · Urogenital Diseases (8) · Female Urogenital Diseases (7) · Glomerulonephritis (7) · Kidney Diseases (7) · Male Urogenital Diseases (7) · Nephritis (7) · Urologic Diseases (7) · Vascular Diseases (7) · Cardiovascular Diseases (6) · Musculoskeletal Diseases (6)
Cholecalciferol (2) · Cyclophosphamide (2) · 2019-nCoV Vaccine mRNA-1273 (1) · 3,3'-diindolylmethane (1) · Adrenal Cortex Hormones (1) · Balneology (1) · COVID-19 Vaccines (1) · CTL019 chimeric antigen receptor (1) · Chloroquine (1) · Electrocardiography (1) · Endoscopy (1) · Hematologic Tests (1) · Hydroxychloroquine (1) · Lisaftoclax (1) · Mycophenolic Acid (1)
Assiut University (10) · Nanjing Bioheng Biotech Co., Ltd. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · National Taiwan University Hospital (2) · Region Skane (2) · ASST Fatebenefratelli Sacco (1) · Alumis Inc (1) · Artiva Biotherapeutics, Inc. (1) · Ascentage Pharma Group Inc. (1) · Children's Hospital of Philadelphia (1) · Chinese University of Hong Kong (1) · Cullinan Therapeutics Inc. (1) · Curocell Inc. (1) · Fayoum University (1) · Hospital for Special Surgery, New York (1)
United States (15) · China (5) · Canada (4) · Egypt (4) · Bulgaria (3) · Georgia (3) · Hungary (3) · Spain (3) · Taiwan (3) · Argentina (2) · France (2) · Germany (2) · Poland (2) · Romania (2) · Sweden (2)
Ahmed Aeltaih, MBBch (1) · Antonio Luca Brucato, Prof (1) · Ayat Salah Ahmed Barakat (1) · Caitlin Elgarten, MD (1) · Chung-Yi Hu, PhD (1) · Cynthia Aranow, MD (1) · Diane Kamen, MD (1) · Eldon Jupe, Ph.D. (1) · Eliza Chakravarty, MD (1) · Gellan Karamallah Ramadan Ahmed, lecturer of psychiatry (1) · Ghada M Ezzat, PhD (1) · Handono Kalim, Prof. (1) · Ines Colmegna, DR (1) · Jehns Martineus, MD (1) · Jianghua Chen, MD (1)
PMID 10192509, PMID 10342711, PMID 11180122, PMID 11508435, PMID 12765470, PMID 15368347, PMID 15638045, PMID 16980725, PMID 18195175, PMID 18625446, PMID 19037607, PMID 20538173, PMID 20696016, PMID 21602492, PMID 21969015, PMID 22369270, PMID 22626746, PMID 22832822, PMID 24268009, PMID 25440767, PMID 25777546, PMID 25980596, PMID 26118732, PMID 26962815, PMID 27737891, PMID 28081972, PMID 28533778, PMID 28552512, PMID 28781372, PMID 28843719, PMID 28899797, PMID 29325173, PMID 29367615, PMID 29431056, PMID 29445400, PMID 30137589, PMID 30309472, PMID 30454753, PMID 30620419, PMID 30643918, PMID 30784137, PMID 30873413, PMID 30886963, PMID 31685414, PMID 31974366, PMID 32129195, PMID 32153796, PMID 32806663, PMID 33556767, PMID 35014577
2023 (1), UM1AI110494 (1)